The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller
Open accessAbstract
BACKGROUND: We sought to analyze the prognostic significance of the new International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) lung adenocarcinoma (ADC) classification for patients undergoing resection for small (≤2cm) lung ADC and to investigate whether histologic subtyping can predict recurrence after limited resection (LR) vs lobectomy (LO). METHODS: Comprehensive histologic subtyping was performed according to the IASLC/ATS/ERS classification on all consecutive patients who underwent LR or LO for small lung ADC between 1995 and 2009 at Memorial Sloan-Kettering Cancer Center. Clinical characteristics and pathologic data were retrospectively evaluated for 734 consecutive patients (LR: 258; LO: 476). Cumulative incidence of recurrence (CIR) was calculated using competing risks analysis and compared across groups using Grey's test. All statistical tests were two-sided. RESULTS: Application of IASLC/ATS/ERS lung ADC histologic subtyping to predict recurrence demonstrates that, in the LR group but not in the LO group, micropapillary (MIP) component of 5% or greater was associated with an increased risk of recurrence, compared with MIP component of less than 5% (LR: 5-year CIR = 34.2%, 95% confidence interval [CI] = 23.5% to 49.7% vs 5-year CIR = 12.4%, 95% CI = 6.9% to 22.1%, P < .001; LO: 5-year CIR = 19.1%, 95% CI = 12.0% to 30.5% vs 15-year CIR = 12.9%, 95% CI = 7.6% to 21.9%, P = .13). In the LR group, among patients with tumors with an MIP component of 5% or greater, most recurrences (63.4%) were locoregional; MIP component of 5% or greater was statistically significantly associated with increased risk of local recurrence when the surgical margin was less than 1cm (5-year CIR = 32.0%, 95% CI = 18.6% to 46.0% for MIP ≥ 5% vs 5-year CIR = 7.6%, 95% CI = 2.3% to 15.6% for MIP < 5%; P = .007) but not when surgical margin was 1cm or greater (5-year CIR = 13.0%, 95% CI = 4.1% to 22.1% for MIP ≥ 5% vs 5-year CIR = 3.4%, 95% CI = 0% to 7.7% for MIP < 5%; P = .10). CONCLUSIONS: Application of the IASLC/ATS/ERS classification identifies the presence of an MIP component of 5% or greater as independently associated with the risk of recurrence in patients treated with LR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Self-citationGoldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Self-citationRandomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer
Ginsberg, R. J., & Rubinstein, L. V. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00537-u · Cited by 3,006
Yoshizawa, A., Motoi, N., Riely, G. J., Sima, C. S., Gerald, W. L., Kris, M. G., Park, B. J., Rusch, V. W., & Travis, W. D. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.232 · Cited by 976
Self-citation(2016) · Diagnostic Imaging: Nuclear Medicine · doi:10.1016/b978-0-323-37753-9.50111-0 · Cited by 855
Cited by
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Self-citationKadota, K., Nitadori, J.-I., Sima, C. S., Ujiie, H., Rizk, N. P., Jones, D. R., Adusumilli, P. S., & Travis, W. D. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000486 · Cited by 673
Self-citationMoreira, A. L., Ocampo, P. S. S., Xia, Y., Zhong, H., Russell, P. A., Minami, Y., Cooper, W. A., Yoshida, A., Bubendorf, L., Papotti, M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.001 · Cited by 559
Self-citationClassification and Pathology of Lung Cancer
Zheng, M. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.003 · Cited by 398
Eguchi, T., Kameda, K., Lu, S., Bott, M. J., Tan, K. S., Montecalvo, J., Chang, J. C., Rekhtman, N., Jones, D. R., Travis, W. D., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.005 · Cited by 300
Self-citation
Metadata
- Authors
- Nitadori, J.-I., Bograd, A. J., Kadota, K., Sima, C. S., Rizk, N. P., Morales, E. A., Rusch, V. W., Travis, W. D., & Adusumilli, P. S.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-13
- Volume
- 105
- Issue
- 16
- Pages
- 1212-1220
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2098830176
- Cited by
- 323
- References
- 23
- FWCI
- 17.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller. https://app.cochat.ai/papers/10.1093/jnci/djt166
- The paper
- Nitadori, J.-I., Bograd, A. J., Kadota, K., Sima, C. S., Rizk, N. P., Morales, E. A., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2013). Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.